Clinical study to evaluate the efficacy, pharmacokinetics and safety of immunoglobulin intravenous (human) 10% (NewGam) in patients with primary immunodeficiency diseases.

Trial Profile

Clinical study to evaluate the efficacy, pharmacokinetics and safety of immunoglobulin intravenous (human) 10% (NewGam) in patients with primary immunodeficiency diseases.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2011

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Bacterial infections; Immunodeficiency disorders
  • Focus Therapeutic Use
  • Sponsors Octapharma
  • Most Recent Events

    • 17 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top